Alert: Alzheimer’s Drug Fails In Clinical Trial - Stocks Sink

Another clinical trial failure for an Alzheimer’s Disease in a late stage trial triggered a pre-market sell-off. Both Biogen (BIIB) and Lilly (LLY) drugs in development are engineered antibodies that attack beta amyloid targets in the brain.

As of 10.25am 11/23

ACIU $11.90 down 13.14%

BIIB $304 down 4.4%

LLY $67.16 down 11.4%

The sell-off appears to limited to direct players for now. The IBB is flat at $281.16 and the XBI is actually up 0.57% to $65. Mid-caps are in the green: SGEN, TSRO.

AC Immune (ACIU) A Swiss based clinical stage biopharma Company is focused in AD drugs with a pipeline of six drugs including one for prevention is partnered with Genentech (Roche) and Janssen (JNJ).

The biotech sector is underperforming YTD and this news will undoubtedly bring in sellers.

Update at the close.

Disclosure: long ABBV, BMY, GILD.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Craig Newman 4 years ago Member's comment

What are the chances of $BIIB and $TSRO being bought out? They have long been targets, or at least rumored to be, for consolidation.